A 3-day-old neonate with severe hypertriglyceridemia from novel mutations of the GPIHBP1 gene

•Chylomicronemia was incidentally found in a 3-day-old breastfed neonate.•Switching to a low-fat formula milk greatly reduced plasma triglyceride levels.•The neonate was compound heterozygous for 2 novel GHPHBP1 mutations.•The heterozygous parents of the patient had a normal plasma lipid profile.

BackgroundFamilial chylomicronemia is a genetic defect of the intravascular lipolysis of triglyceride (TG)-rich lipoproteins. Intravascular lipolysis involves the TG-hydrolase lipoprotein lipase (LPL) as well as other factors such as apolipoprotein CII and apolipoprotein AV (activators of LPL), GPIHBP1 (the molecular platform required for LPL activity on endothelial surface), and LMF1 (a factor required for intracellular formation of active LPL).MethodsWe sequenced the familial chylomicronemia candidate genes in a neonate with chylomicronemia.ResultsA 3-day-old newborn was found to have chylomicronemia (plasma TG 18.8 mmol/L, 1.667 mg/dL). The discontinuation of breastfeeding for 24 hours reduced plasma TG to 2.3 mmol/L (201 mg/dL), whereas its resumption induced a sharp TG increase (7.9 mmol/L, 690 mg/dL). The child was switched to a low-fat diet, which was effective in maintaining TG level below 3.5 mmol/L (294 mg/dL) during the first months of life. The child was found to be a compound heterozygous for 2 novel mutations in GPIHBP1 gene. The first mutation was a 9-bp deletion and 4-bp insertion in exon 2, causing a frameshift that abolished the canonical termination codon TGA. The predicted translation product of the mutant messenger RNA is a peptide that contains 51 amino acids of the N-terminal end of the wild-type protein followed by 252 novel amino acids. The second mutation was a nucleotide change (c.319T>C), causing an amino acid substitution p.(Ser107Pro) predicted in silico to be damaging.ConclusionsGPIHBP1 mutations should be considered in neonates with chylomicronemia negative for mutations in LPL gene.